Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Rheumatic Disorders Treatment Market: By Disease, By Treatment, Biologic Response Modifiers, TNF Inhibitors, Interleukin Inhibitors, JAK inhibitors), and Others), and Geography
Rheumatic Disorders Treatment Market size was valued at US$ 65.02 billion in 2023, growing at a CAGR of 6.2% from 2024 to 2030. The global market provides a detailed overview and that can be segmented by disease and by treatment. By disease, the global rheumatic disorders treatment market has been segmented into Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gout, and Others. The Rheumatoid Arthritis segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. This is due to the increasing prevalence of rheumatoid arthritis. Based on treatment, the global rheumatic disorders treatment market is segmented into Narcotic Analgesics, NSAIDS, Corticosteroids, and Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Among these, the Disease-Modifying Anti-Rheumatic Drugs (DMARDs) segment is expected to have the fastest-growing market during the forecast period. according to Precision Business Insights. The rise in the incidence of a number of indications within the rheumatic disorders and increase in prevalence of geriatric population are the major factors that are driving the growth of the market in 2022 and are expected to maintain a significant CAGR in the upcoming years.
Rheumatic Disorders Treatment Market Key Development:
Study Period
2024-2030Base Year
2023CAGR
6.2%Largest Market
North AmericaFastest Growing Market
Europe
Growing geriatric populations, increasing prevalence of rheumatic disorders are anticipated to propel the market growth over the forecast years.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 65.02 billion |
Market CAGR |
6.2% |
By Disease |
|
By Treatment |
|
By Region |
|
Download Free Sample Report
The rheumatic disorders treatment market size was valued at US$ 65.02 billion in 2023
The rheumatic disorders treatment market key players are: AbbVie Amgen Astellas AstraZeneca Bristol-Myers Squibb ChemoCentryx Corbus Pharmaceuticals Eli Lilly Gilead Sciences GlaxoSmithKline Johnson & Johnson Novartis Pfizer Roche Selecta Biosciences UCB
The rheumatic disorders treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Rheumatic Disorders Treatment Market Introduction |
2.1. Global Rheumatic Disorders Treatment Market Taxonomy |
2.2. Global Rheumatic Disorders Treatment Market Definitions |
2.2.1. By Disease |
2.2.2. By Treatment |
2.2.3. By Distribution Channel |
3. Global Rheumatic Disorders Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Rheumatic Disorders Treatment Market Dynamics – Factors Impact Analysis |
4. Global Rheumatic Disorders Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Rheumatic Disorders Treatment Market Forecast, By Disease, 2019 - 2023 and Forecast, 2024 - 2030 |
5.1. Rheumatoid Arthritis |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Osteoarthritis |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Osteoporosis |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Systemic Lupus Erythematosus |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Psoriatic Arthritis |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Gout |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Others |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6. Global Rheumatic Disorders Treatment Market Forecast, By Treatment, 2019 - 2023 and Forecast, 2024 - 2030 |
6.1. Narcotic Analgesics |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. NSAIDS |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Corticosteroids |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs) |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Biologic Response Modifiers |
6.5.1. Monoclonal Antibodies |
6.5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.1.3. Market Opportunity Analysis |
6.5.2. TNF Inhibitors |
6.5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.2.3. Market Opportunity Analysis |
6.5.3. Interleukin Inhibitors |
6.5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3.3. Market Opportunity Analysis |
6.5.4. JAK Inhibitors |
6.5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.4.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7. Global Rheumatic Disorders Treatment Market Forecast, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Rheumatic Disorders Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 |
North America |
Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
Market Opportunity Analysis |
Europe |
Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
Market Opportunity Analysis |
Asia Pacific |
Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
Market Opportunity Analysis |
Latin America |
Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
Market Opportunity Analysis |
The Middle East & Africa |
Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
Market Opportunity Analysis |
9. Global Rheumatic Disorders Treatment Market - Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Region, 2024 - 2030 |
North America Rheumatic Disorders Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
Disease Analysis (2019 - 2023) and Forecast (2024 - 2030 |
Rheumatoid Arthritis |
Osteoarthritis |
Osteoporosis |
Systemic Lupus Erythematosus |
Psoriatic Arthritis |
Gout |
Others |
Treatment Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Narcotic Analgesics |
NSAIDS |
Corticosteroids |
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) |
Biologic Response Modifiers |
Monoclonal Antibodies (mAb) |
TNF Inhibitors |
Interleukin (IL) Inhibitors (IL) |
JAK inhibitors |
Others |
Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Hospital Pharmacies |
Retail Pharmacies |
Online Pharmacies |
Country Analysis (2019 - 2023) and Forecast (2024 - 2030) |
U.S. |
Canada |
10. North America Rheumatic Disorders Treatment Market - Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2024 - 2030 |
North America Rheumatic Disorders Treatment Market Dynamics – Trends |
Europe Rheumatic Disorders Treatment Market Analysis, 2019 - 2023 and Forecast, 2019 - 2023 |
Disease Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Rheumatoid Arthritis |
Osteoarthritis |
Osteoporosis |
Systemic Lupus Erythematosus |
Psoriatic Arthritis |
Gout |
Others |
Treatment Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Narcotic Analgesics |
NSAIDS |
Corticosteroids |
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) |
Biologic Response Modifiers |
Monoclonal Antibodies (mAb) |
TNF Inhibitors |
Interleukin (IL) Inhibitors (IL) |
JAK inhibitors |
Others |
Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Hospital Pharmacies |
Retail Pharmacies |
Online Pharmacies |
Country Analysis (2019 - 2023) and Forecast (2024 - 2030) |
U.K. |
Germany |
France |
Italy |
Spain |
Russia |
Rest of Europe |
11. Europe Rheumatic Disorders Treatment Market - Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2024 - 2030 |
Europe Rheumatic Disorders Treatment Market Dynamics – Trends |
Asia Pacific Rheumatic Disorders Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
Disease Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Rheumatoid Arthritis |
Osteoarthritis |
Osteoporosis |
Systemic Lupus Erythematosus |
Psoriatic Arthritis |
Gout |
Others |
Treatment Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Narcotic Analgesics |
NSAIDS |
Corticosteroids |
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) |
Biologic Response Modifiers |
Monoclonal Antibodies (mAb) |
TNF Inhibitors |
Interleukin (IL) Inhibitors (IL) |
JAK inhibitors |
Others |
Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Hospital Pharmacies |
Retail Pharmacies |
Online Pharmacies |
Country Analysis (2019 - 2023) and Forecast (2024 - 2030) |
China |
Japan |
India |
ASEAN Counties |
Philippines |
Rest of Asia Pacific |
12. Asia Pacific Rheumatic Disorders Treatment Market - Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2024 - 2030 |
Asia Pacific Rheumatic Disorders Treatment Market Dynamics – Trends |
Latin America Rheumatic Disorders Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
Disease Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Rheumatoid Arthritis |
Osteoarthritis |
Osteoporosis |
Systemic Lupus Erythematosus |
Psoriatic Arthritis |
Gout |
Others |
Treatment Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Narcotic Analgesics |
NSAIDS |
Corticosteroids |
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) |
Biologic Response Modifiers |
Monoclonal Antibodies (mAb) |
TNF Inhibitors |
Interleukin (IL) Inhibitors (IL) |
JAK inhibitors |
Others |
Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Hospital Pharmacies |
Retail Pharmacies |
Online Pharmacies |
Country Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Mexico |
Brazil |
Argentina |
Chile |
Rest of Latin America |
13. Latin America Rheumatic Disorders Treatment Market - Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2024 - 2030 |
Latin America Rheumatic Disorders Treatment Market Dynamics – Trends |
Middle East and Africa Rheumatic Disorders Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
Disease Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Rheumatoid Arthritis |
Osteoarthritis |
Osteoporosis |
Systemic Lupus Erythematosus |
Psoriatic Arthritis |
Gout |
Others |
Treatment Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Narcotic Analgesics |
NSAIDS |
Corticosteroids |
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) |
Biologic Response Modifiers |
Monoclonal Antibodies (mAb) |
TNF Inhibitors |
Interleukin (IL) Inhibitors (IL) |
JAK inhibitors |
Others |
Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) |
Hospital Pharmacies |
Retail Pharmacies |
Online Pharmacies |
Country Analysis (2019 - 2023) and Forecast (2024 - 2030) |
GCC Countries |
South Africa |
Saudi Arabia |
Turkey |
Rest of MEA |
14. Middle East and Africa Rheumatic Disorders Treatment Market - Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2024 - 2030 |
Middle East and Africa Rheumatic Disorders Treatment Market Dynamics – Trends |
15. Competition Landscape |
Strategic Dashboard of Top Market Players |
Company Profiles (Introduction, Financial Analysis, Key Developments, Strategies, and SWOT Analysis) |
AbbVie |
Amgen |
Astellas |
AstraZeneca |
Bristol-Myers Squibb |
ChemoCentryx |
Corbus Pharmaceuticals |
Eli Lilly |
Gilead Sciences |
GlaxoSmithKline |
Johnson & Johnson |
Novartis |
Pfizer |
Roche |
Selecta Biosciences |
UCB |
16. Research Methodology |
17. Key Assumptions and Acronyms |
Key Market Players